liraglutide + lorcaserin + naltrexone + bupropion + orlistat + phentermine + topiramate

This is a hypothetical combination drug consisting of seven active pharmaceutical ingredients, each approved individually or in pairs for the treatment of obesity and weight management. The components are: - **Liraglutide** (a GLP-1 receptor agonist) - **Lorcaserin** (a selective serotonin 2C receptor agonist; withdrawn from the US market due to safety concerns) - **Naltrexone** (an opioid receptor antagonist) - **Bupropion** (a norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist) - **Orlistat** (a pancreatic lipase inhibitor) - **Phentermine** (a sympathomimetic amine, primarily a norepinephrine and dopamine releasing agent) - **Topiramate** (an anticonvulsant with multiple mechanisms including carbonic anhydrase inhibition, AMPA receptor antagonism, and GABA-A receptor modulation). This hypothetical combination aims to target multiple pathways involved in appetite regulation, energy expenditure, and fat absorption for comprehensive weight management.